Imara M&A

Highly Distinguished & Industry-Leading Team with Top-Tier Advisors and Investors Sam Kintz, MBA Co-founder and CEO abbvie Genentech A Member of the Roche Group Joe Lyssikatos, PhD Co-founder and CSO ARRAY Genentech A Member of the Roche Group BIOPHARMA Stefan Gross, PhD VP, Biology blueprint ARRAY BOPHARMA Anne Thomas VP, Clinical Operations Five Príme GILEAD Leadership Team Anish Patel, PharmD Co-founder and COO abbvie pharmacyclics Wei Deng, PhD VP, Biometrics Five Príme GILEAD lan Scott, PhD VP, CMC zentalis ARRAY BIOPHARMA * To be added to the Board of Directors at the close of the proposed transaction Helen Collins, MD CMO Five Príme GILEAD Andy Ren, PhD VP, Chemistry ARRAY BIOPHARMA Qi Wang, PhD VP, Clinical Pharmacology Bristol Myers Squibb Jazz Pharmaceuticals Ben Hohl CFO Goldman Sachs Board of the Directors Sam Kintz, MBA Enliven Therapeutics Joe Lyssikatos, PhD Enliven Therapeutics Rishi Gupta, JD OrbiMed Andy Schwab 5AM Ventures Andy Phillips, PhD Cormorant Asset Management Mika Kakefuda Derynck, MD Amunix Genentech Jake Bauer, MBA Myokardia Rich A. Heyman, PhD Aragon Pharmaceuticals, Seragon Pharmaceuticals Rahul Ballal* Current CEO of Imara Scientific Advisors Brian Druker, MD Oregon Health & Science University Rich A. Heyman, PhD Aragon Pharmaceuticals, Seragon Pharmaceuticals Lori Kunkel, MD Loxo Oncology, Pharmacyclics Kevin Koch, PhD Array Biopharma, Edgewise Therapeutics Current Investors OrbiMed Healthcare Fund Management SURVEYOR Roche Venture Fund Connecting Innovation to Value BOXER CAPITAL AM VENTURES 5 INVESTORS Cormorant Asset Management SHEATREE CAPITAL LOGOS CAPITAL Janus Henderson CO 6

View entire presentation